Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in patients who experienced co-occurring myositis and myasthenia gravis, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.
Continue Reading this article here
